摘要
化疗作为恶性肿瘤治疗的主要手段之一,在临床应用广泛,但由于其非特异性杀伤肿瘤细胞,会引起免疫抑制及全身毒副作用。近年来多项研究报告低剂量传统化疗药物不仅不会造成免疫抑制,反而会通过抑制骨髓源性抑制细胞(MDSCs)或促进免疫原性细胞死亡(ICD),增强人体抗肿瘤免疫反应。其次,随着纳米技术的发展,刺激响应药物递送系统能够进一步降低化疗药物的毒副作用,提高药物在靶组织中的聚集,提高治疗效果。该文就传统化疗药物的免疫增效作用及刺激响应药物递送系统近年来的研究进展进行综述。
Chemotherapy,as one of the main means of cancer treatment,is widely used in clinic.It can cause immunosuppression and systemic side effects due to its nonspecific killing tumor cells.In recent years,it has been widely reported that low-dose traditional chemotherapeutic drugs not only can′t cause immunosuppression,but also enhance the anti-tumor immune responses by inhibiting myeloid-derived suppressor cells(MDSC)or promoting immunogenic cell death(ICD).Secondly,with the development of nanotechnology,the stimuli-responsive drug delivery systems can further reduce the toxic and side effects of chemotherapeutic drugs,increase the aggregation of drugs in target tissues and improve the therapeutic effects.This article reviews the study progresses in the immunomodulation property of traditional chemotherapeutic drugs and stimuli-responsive drug delivery systems in recent years.
作者
郑君(综述)
张亮
王志刚(审校)
ZHENG Jun;ZHANG Liang;WANG Zhigang(Institute of Ultrasound Imaging,Chongqing Medical University,Chongqing Key Laboratory of Ultrasound Molecular Imaging,Chongqing 400010,China)
出处
《重庆医学》
CAS
2021年第11期1937-1941,共5页
Chongqing medicine
基金
国家自然科学基金项目(31630026)。
作者简介
郑君(1995-),在读硕士,主要从事诊疗一体化纳米粒研究;通信作者:王志刚,E-mail:wzg62942443@163.com。
